LUGPA Leaders Convene Panel to Optimize Role of ADT in Advanced Prostate Cancer

Dear LUGPA Colleagues,
We are pleased to announce the publication of "Optimizing the Role of Androgen Deprivation Therapy in Advanced Prostate Cancer: Challenges Beyond the Guidelines" in The Prostate (Prostate. 2020 Mar 4. doi: 10.1002/pros.23967),  Neal D. Shore, MD, et al. 

Dr. Shore, Past President of LUGPA (2016-2018), led a 14- member expert panel of LUGPA and Academic urologists and medical oncologists, which discussed key questions on the use of ADT in clinical practice – addressing questions that are not always answered by prior published guidelines. 

"Our goal was to address some of the clinical challenges we face in practice," said Dr. Shore. "We were attempting to  supplement possible gaps within existing guideline recommendations regarding the use of ADT. Our goal was to provide a user-friendly reference for clinicians who are managing prostate cancer  and the role of ADT across the entire prostate cancer continuum."

The panel convened in September 2018 and, after a series of presentations and discussion, voted on numerous issues regarding ADT use, including primary ADT in newly diagnosed disease, neoadjuvant ADT prior to radical prostatectomy or radiation therapy, ADT as salvage therapy, ADT for biochemical recurrence post definitive therapy, ADT for castrate-sensitive prostate cancer (CSPC), castrate-resistant prostate cancer (CRPC), and the management of ADT adverse events and prevention strategies.

In 2019, Dr. Shore convened a second panel of experts to review the management of mCRPC. This manuscript is pending publication. "We hope that all of our colleagues will find these 2 publications to be a valuable resource as they make treatment and management  decisions for their prostate cancer patients," said Dr. Shore.

Article authors were: Neal D. Shore, MD, FACS; Emmanuel S. Antonarakis, MD; Michael S. Cookson, MD; E. David Crawford, MD; Alicia K. Morgans, MD; David M. Albala, MD; Jason Hafron, MD; Richard G. Harris, MD; Daniel Saltzstein, MD; Gordon A. Brown, DO; Jonathan Henderson, MD; Benjamin Lowentritt, MD; Jeffrey M. Spier, MD; Raoul Concepcion, MD, FACS. The project was enabled by the generous support of an unrestricted grant from Tolmar Pharmaceuticals.

Read the entire article here.